1. Home
  2. WVE vs VOR Comparison

WVE vs VOR Comparison

Compare WVE & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$5.55

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

HOLD

Current Price

$20.82

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WVE
VOR
Founded
2012
2015
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
WVE
VOR
Price
$5.55
$20.82
Analyst Decision
Strong Buy
Buy
Analyst Count
16
10
Target Price
$29.81
$45.33
AVG Volume (30 Days)
2.3M
1.2M
Earning Date
04-28-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,704,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$85.67
N/A
P/E Ratio
N/A
N/A
Revenue Growth
149.43
N/A
52 Week Low
$5.02
$1.62
52 Week High
$21.73
$49.95

Technical Indicators

Market Signals
Indicator
WVE
VOR
Relative Strength Index (RSI) 38.55 61.60
Support Level $5.49 $11.62
Resistance Level $6.48 $22.22
Average True Range (ATR) 0.24 1.44
MACD -0.01 0.11
Stochastic Oscillator 25.16 82.31

Price Performance

Historical Comparison
WVE
VOR

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About VOR Vor Biopharma Inc.

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Share on Social Networks: